Markets Stifel starts Angion Biomedica at buy; PT $40 Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)... March 2, 2021